eXoZymes, Inc.·Healthcare
LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Commercial Officer, Damien Perriman was featured on the latest episode of the industry leading Grow Everything podcast to discuss the company's first spinout, NCTx, and how eXoZymes is building a repeatable commercialization model for high-value natural products. The Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder.
Management to Host Conference Call Today at 5:30 PM Eastern LOS ANGELES, CA / ACCESS Newswire / March 31, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - provides an update on operations through the fiscal year ended December 31, 2025. Michael Heltzen, CEO of eXoZymes, states, "We've moved beyond our ‘big idea' potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe sets us apart.
LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these results will be issued prior to the call.
LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes' technology at pilot scale and achieved results consistent with - and in some cases exceeding - earlier internal runs. Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently.
LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Perriman will present a solution for scaling production of NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications. The presentation will focus on NCT's potential role in metabolic health and its emerging relevance in the rapidly evolving landscape of food, supplements, and longevity-focused wellness solutions.
eXoZymes (NASDAQ: EXOZ - Get Free Report) and Curis (NASDAQ: CRIS - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation. Insider and Institutional Ownership 30.0% of Curis shares are
